2019
Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west
Lu J, Zhang XP, Zhong BY, Lau WY, Madoff DC, Davidson JC, Qi X, Cheng SQ, Teng GJ. Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west. The Lancet Gastroenterology & Hepatology 2019, 4: 721-730. PMID: 31387735, DOI: 10.1016/s2468-1253(19)30178-5.Peer-Reviewed Original ResearchMeSH KeywordsAnilidesAntibodies, Monoclonal, HumanizedAntineoplastic AgentsCarcinoma, HepatocellularChemoembolization, TherapeuticEndovascular ProceduresHepatectomyHepatic ArteryHumansInfusions, Intra-ArterialLiver NeoplasmsLiver TransplantationNivolumabPatient Care TeamPhenylurea CompoundsPortal VeinPyridinesQuinolinesRadiotherapy, AdjuvantSorafenibStentsVenous ThrombosisConceptsPortal vein tumor thrombosisTumor thrombosisHepatocellular carcinomaOptimise treatment strategiesTranscatheter arterial therapyAdvanced hepatocellular carcinomaManagement of patientsArterial therapySurgical treatmentTreatment strategiesPhysician preferenceNovel treatmentsCarcinomaThrombosisMultidisciplinary teamPatientsReimbursement schemesTreatmentRevascularisationComorbiditiesManagementPrognosisRadiotherapyActive managementTherapy
2011
Phase I Trial of Hepatic Arterial Infusion of Nanoparticle Albumin–Bound Paclitaxel: Toxicity, Pharmacokinetics, and Activity
Fu S, Naing A, Moulder SL, Culotta KS, Madoff DC, Ng CS, Madden TL, Falchook GS, Hong DS, Kurzrock R. Phase I Trial of Hepatic Arterial Infusion of Nanoparticle Albumin–Bound Paclitaxel: Toxicity, Pharmacokinetics, and Activity. Molecular Cancer Therapeutics 2011, 10: 1300-1307. PMID: 21571911, DOI: 10.1158/1535-7163.mct-11-0259.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAlbuminsAntineoplastic AgentsFemaleHumansInfusions, Intra-ArterialLiver NeoplasmsMaleMiddle AgedPaclitaxelRadiographyTreatment OutcomeConceptsHepatic arterial infusionNab-paclitaxelHepatic extractionArterial infusionDose levelsNanoparticle Albumin-Bound PaclitaxelFirst-pass hepatic extractionPredominant liver metastasesCommon adverse eventsAdvanced cancer patientsAlbumin-Bound PaclitaxelDose-limiting toxicityPeak concentrationHighest dose levelStable diseaseAdverse eventsLiver involvementLiver metastasesPartial responseI trialComparative pharmacokinetic studyHepatic metastasesPoor outcomeCancer patientsNanoparticle albuminHigh Survival Rate After Two-Stage Resection of Advanced Colorectal Liver Metastases: Response-Based Selection and Complete Resection Define Outcome
Brouquet A, Abdalla EK, Kopetz S, Garrett CR, Overman MJ, Eng C, Andreou A, Loyer EM, Madoff DC, Curley SA, Vauthey JN. High Survival Rate After Two-Stage Resection of Advanced Colorectal Liver Metastases: Response-Based Selection and Complete Resection Define Outcome. Journal Of Clinical Oncology 2011, 29: 1083-1090. PMID: 21263087, PMCID: PMC3068054, DOI: 10.1200/jco.2010.32.6132.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsChemotherapy, AdjuvantColorectal NeoplasmsFemaleHepatectomyHumansKaplan-Meier EstimateLiver NeoplasmsMaleMiddle AgedNeoadjuvant TherapyPatient SelectionRetrospective StudiesRisk AssessmentRisk FactorsSurvival RateTexasTime FactorsTomography, X-Ray ComputedTreatment OutcomeConceptsAdvanced colorectal liver metastasesTwo-stage resectionColorectal liver metastasesLiver metastasesComplete resectionSurvival rateMedical groupMajor postoperative complicationsSurvival of patientsChemotherapy initiationNonsurgical patientsOnly chemotherapyPostoperative complicationsColorectal metastasesMetastatic diseaseObjective responseWorse survivalTreat analysisGood respondersExcellent outcomesTSR groupInclusion criteriaResectionPatientsChemotherapy
2009
Hepatic Arterial Embolization and Chemoembolization for Imatinib-Resistant Gastrointestinal Stromal Tumors
Kobayashi K, Szklaruk J, Trent JC, Ensor J, Ahrar K, Wallace MJ, Madoff DC, Murthy R, Hicks ME, Gupta S. Hepatic Arterial Embolization and Chemoembolization for Imatinib-Resistant Gastrointestinal Stromal Tumors. American Journal Of Clinical Oncology 2009, 32: 574-581. PMID: 19636238, DOI: 10.1097/coc.0b013e31819cca35.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsBenzamidesDrug Resistance, NeoplasmEmbolization, TherapeuticFemaleGastrointestinal NeoplasmsGastrointestinal Stromal TumorsHepatic ArteryHumansImatinib MesylateLiver NeoplasmsMaleMiddle AgedNeoplasm StagingPiperazinesPrognosisProtein-Tyrosine KinasesPyrimidinesRetrospective StudiesSurvival RateTreatment OutcomeConceptsImatinib-resistant gastrointestinal stromal tumorsGastrointestinal stromal tumorsProgressive liver metastasesHepatic arterial embolizationResponse Evaluation CriteriaOverall survival rateStromal tumorsArterial embolizationLiver metastasesSurvival rateRadiologic responseStable diseaseExtrahepatic metastasesPartial responseSurvival timeMedian progression-free survival timeSolid tumorsProgression-free survival ratesMedian overall survival timeProgression-free survival timeResponse criteriaCox proportional hazards modelAppreciable survival benefitEfficacy of embolotherapyProgression-free survival
2007
Hepatic Yttrium-90 Radioembolotherapy in Metastatic Colorectal Cancer Treated with Cetuximab or Bevacizumab
Murthy R, Eng C, Krishnan S, Madoff DC, Habbu A, Canet S, Hicks ME. Hepatic Yttrium-90 Radioembolotherapy in Metastatic Colorectal Cancer Treated with Cetuximab or Bevacizumab. Journal Of Vascular And Interventional Radiology 2007, 18: 1588-1591. PMID: 18057297, DOI: 10.1016/j.jvir.2007.08.015.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBevacizumabCetuximabColorectal NeoplasmsCombined Modality TherapyFemaleHumansLiver NeoplasmsMaleMicrospheresMiddle AgedRadiopharmaceuticalsTomography, Emission-Computed, Single-PhotonTomography, X-Ray ComputedTreatment OutcomeYttrium RadioisotopesConceptsColorectal cancerTreatment experienceAdvanced unresectable colorectal cancerUnresectable colorectal cancerMetastatic colorectal cancerCohort of patientsYttrium-90 microspheresSystemic therapyBiologic agentsDrug AdministrationHepatic neoplasiaCetuximabPatientsCancerBevacizumabChemotherapyNeoplasiaTherapyCohortPhysiciansAdministration
2006
Update on the Management of Neuroendocrine Hepatic Metastases
Madoff DC, Gupta S, Ahrar K, Murthy R, Yao JC. Update on the Management of Neuroendocrine Hepatic Metastases. Journal Of Vascular And Interventional Radiology 2006, 17: 1235-1250. PMID: 16923972, DOI: 10.1097/01.rvi.0000232177.57950.71.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsBrachytherapyCatheter AblationChemoembolization, TherapeuticClinical Trials as TopicCryosurgeryEthanolHepatectomyHumansLiver NeoplasmsLiver TransplantationNeoplasms, Unknown PrimaryNeuroendocrine TumorsPractice Guidelines as TopicRadiology, InterventionalTomography, X-Ray ComputedTreatment OutcomeConceptsNeuroendocrine tumorsHepatic metastasesLong indolent courseYear of diagnosisMajority of patientsTime of diagnosisCare of patientsUnusual clinical presentationNeuroendocrine hepatic metastasesTumor growth patternMost patientsIndolent courseClinical presentationRespiratory tractPatientsOrgan systemsMetastasisDiagnosisImage-guided interventionsGrowth patternMalignancyTumorsTractCare